Oncolytics Biotech Inc. (ONCY): Price and Financial Metrics

Oncolytics Biotech Inc. (ONCY): $1.78

-0.05 (-2.73%)

POWR Rating

Component Grades













Add ONCY to Watchlist
Sign Up

Industry: Biotech



in industry

ONCY Stock Price Chart Interactive Chart >

Price chart for ONCY

ONCY Price/Volume Stats

Current price $1.78 52-week high $2.28
Prev. close $1.83 52-week low $0.80
Day low $1.77 Volume 87,561
Day high $1.83 Avg. volume 190,800
50-day MA $1.71 Dividend yield N/A
200-day MA $1.35 Market Cap 109.16M

Oncolytics Biotech Inc. (ONCY) Company Bio

Oncolytics Biotech Inc. discovers and develops pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The Company is focusing on the development of the reovirus known as REOLYSIN as a potential cancer therapeutic.

ONCY Latest News Stream

Event/Time News Detail
Loading, please wait...

ONCY Latest Social Stream

Loading social stream, please wait...

View Full ONCY Social Stream

Latest ONCY News From Around the Web

Below are the latest news stories about ONCOLYTICS BIOTECH INC that investors may wish to consider to help them evaluate ONCY as an investment opportunity.

The Oncolytics Biotech Inc. (ONCY) had a good session last reading, didn’t it?

As of Friday, Oncolytics Biotech Inc.’s (NASDAQ:ONCY) stock closed at $1.63, up from $1.62 the previous day. While Oncolytics Biotech Inc. has overperformed by 0.62%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ONCY rose by 17.27%, with highs and lows ranging from $2.28 to $0.80, […]

US Post News | January 2, 2023

Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?

Here is how DICE Therapeutics, Inc. (DICE) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.

Yahoo | December 16, 2022

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

Oncolytics Biotech® Inc.'s (NASDAQ: ONCY) (TSX: ONC) Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. The data were featured in a poster presented yesterday at the San Antonio Breast Cancer Symposium (SABCS), which is being held at the Henry B. González C

Yahoo | December 8, 2022

What Makes Oncolytics Biotech Inc. (ONCY) a Strong Momentum Stock: Buy Now?

Does Oncolytics Biotech Inc. (ONCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo | December 5, 2022

Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag

Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.

Yahoo | December 2, 2022

Read More 'ONCY' Stories Here

ONCY Price Returns

1-mo 9.20%
3-mo 36.92%
6-mo 42.63%
1-year -6.32%
3-year -32.06%
5-year -67.76%
YTD 9.20%
2022 17.27%
2021 -41.60%
2020 -50.00%
2019 162.98%
2018 -66.46%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7125 seconds.